Psoriatic arthritis (PsA) is a chronic autoimmune disease, causing the immune system to attack the body’s healthy tissue, including tissue of the skin and joints. It’s commonly linked with the skin condition psoriasis; about a third of patients with psoriasis develop psoriatic arthritis. Roughly 125 million individuals worldwide have the condition, and it can start at any age, even in childhood.
Like other forms of arthritis, PsA causes pain, stiffness, swelling and a decline in range of motion. But PsA can also result in silver or gray scaly spots on the scalp, elbows, knees and lower spine, as well as nail depressions or detached fingernails or toenails.
Left untreated, psoriatic arthritis can damage or weaken bones and lead to vision problems, gastrointestinal conditions, shortness of breath and damage to blood vessels and heart muscles.
Roughly 125 million individuals worldwide have the condition, and it can start at any age, even in childhood.”
J&J’s approach to psoriatic arthritis (PsA)
For more than two decades, Johnson & Johnson has been providing patients and physicians with important therapies to treat rheumatoid arthritis (RA) and other rheumatic diseases, beginning with the development of tumor necrosis factor (TNF)-alpha inhibitors and continuing with the establishment of the first interleukin (IL)-12/IL-23 treatment.
We remain focused on complementing our existing portfolio of large-molecule biologics with novel treatments and oral therapeutics in development to provide new options to patients, through a combination of internal research and development, external collaborations, and industry consortia.
The science of PsA is rapidly evolving, and we’ll continue to maintain an important role in this area as an innovator and scientific driver as we explore new mechanisms of action.
